| TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates |
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-05-06 13:20:39 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended March 31, 2025, and provided a corporate update. |
globenewswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting |
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. |
globenewswire.com |
2025-04-28 20:53:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference |
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. |
globenewswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access |
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience |
globenewswire.com |
2025-03-27 09:00:00 |
Czytaj oryginał (ang.) |
| TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 |
Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025. |
seekingalpha.com |
2025-03-07 13:31:43 |
Czytaj oryginał (ang.) |
| TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates |
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2025-03-05 11:25:30 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66 th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and provided a business update. |
globenewswire.com |
2025-03-05 09:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference |
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference |
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time. |
globenewswire.com |
2025-02-18 09:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting |
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism. |
seekingalpha.com |
2025-02-10 05:14:00 |
Czytaj oryginał (ang.) |
| Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks |
The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-01-10 12:35:54 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium |
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics' common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-12-26 09:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank |
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 |
globenewswire.com |
2024-12-23 09:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition |
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) |
globenewswire.com |
2024-12-09 19:45:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years |
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe Magazine on Sunday, December 8, 2024. |
globenewswire.com |
2024-12-05 10:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy |
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial |
globenewswire.com |
2024-12-02 09:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates |
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-11-12 11:26:10 |
Czytaj oryginał (ang.) |
| TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? |
TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-11-07 07:46:11 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition |
All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m. |
globenewswire.com |
2024-11-05 11:15:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting |
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually. |
globenewswire.com |
2024-10-04 13:05:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics to Participate in Upcoming Investor Conferences |
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-29 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates |
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2024-08-12 13:15:37 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning |
globenewswire.com |
2024-08-12 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Updates to its Board of Directors |
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors |
globenewswire.com |
2024-06-14 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference |
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 5, 2024 at 11:00 a.m. Eastern Time. |
globenewswire.com |
2024-05-30 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies |
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning |
globenewswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates |
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.93 per share a year ago. |
zacks.com |
2024-05-13 13:15:47 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update |
First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. |
globenewswire.com |
2024-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors |
Patient dosed with TSC-20 3 -A0201 targeting cancer-associated antigen PRAME On-track to report initial data from the solid tumor clinical trial in 2024 WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been dosed in the Company's Phase 1 trial evaluating TCR-T therapy for the treatment of solid tumors. |
globenewswire.com |
2024-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release |
TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-05-01 15:06:19 |
Czytaj oryginał (ang.) |
| TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting |
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually. |
globenewswire.com |
2024-04-24 20:05:00 |
Czytaj oryginał (ang.) |